Introduction
If you have been researching weight management options, you have probably come across three names again and again – Sema, Tirz and Reta. All three belong to a class of medications called incretin-based therapies, but they differ in how they work, how much research supports them, and what patients can expect from each.
Choosing between them is rarely about picking the strongest option. It is about matching the right medication to your health history, tolerance profile, and long-term goals – under proper medical supervision. Below is a clear, evidence-based comparison of Sema, Tirz and Reta as of 2026.
How Each Medication Works
Sema works on one receptor – the GLP-1 receptor. This helps slow gastric emptying, reduce appetite, and support glucose-dependent insulin release. Sema was the first modern GLP-1 receptor agonist approved specifically for chronic weight management (as Wegovy) in 2021.
Tirz works on two receptors – GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual-action mechanism was designed to produce stronger appetite regulation and better metabolic response. Tirz was approved for weight management (as Zepbound) in 2023.
Reta works on three receptors – GLP-1, GIP and glucagon. This triple-agonist mechanism is the newest of the three and is still under clinical development. Reta is not yet FDA-approved for weight management at the time of writing, but phase 3 trial data has generated significant clinical interest.
What the Research Actually Shows
The most important recent trial is SURMOUNT-5 – the first direct head-to-head comparison between Sema and Tirz – published in the New England Journal of Medicine in 2025. In this trial, 751 adults with obesity but without diabetes were randomly assigned to either Tirz or Sema. After 72 weeks, the Tirz group showed an average weight reduction of 20.2 percent (approximately 22.8 kg / 50 lbs), while the Sema group showed an average weight reduction of 13.7 percent (approximately 15.0 kg / 33 lbs). Waist circumference decreased 18.4 cm with Tirz compared to 13.0 cm with Sema. Gastrointestinal side effects causing discontinuation were less frequent with Tirz (2.7 percent) than with Sema (5.6 percent) (source: American College of Cardiology summary of SURMOUNT-5, NEJM 2025).
For Reta, the strongest data comes from phase 3 obesity trials, which have reported weight reductions of up to 22.5 percent (source: International Journal of Obesity, 2024). However, Reta is still in clinical development and is not currently available through most clinics.
It is also worth noting that clinical trial results do not always translate directly to real-world results. A 2025 real-world evidence review found that 20 to 50 percent of GLP-1 users discontinue within the first year, often due to side effect management, adherence or plateauing (source: PubMed comparative effectiveness review of GLP-1RA-based weight-loss therapies, 2025). Highly adherent patients tend to approach trial-level results.
How to Think About the Choice
Neither the strongest medication nor the newest is automatically the right one. The best choice depends on several factors – your health history (certain conditions like a family history of medullary thyroid cancer or pancreatitis may make one medication more appropriate or peptide therapy inappropriate altogether), your tolerance profile (digestive side effects are common early on), your access and cost considerations (Sema and Tirz have different insurance coverage patterns), and your long-term plan.
Individual response also matters. Some patients do very well on Sema and never need to consider Tirz. Others plateau on Sema and find Tirz fits their body better. Individual response cannot be predicted from clinical trial averages alone.
What a Well-Designed Plan Looks Like
A thoughtful peptide plan starts with proper baseline testing – a metabolic panel, thyroid function, hormone levels and relevant inflammatory markers. This gives your provider a full picture of what your body is doing before adding a medication. From there, dose titration should be gradual, follow-up should be consistent, and lifestyle guidance should be integrated.
At Natural and Holistic Medical Center, our licensed naturopathic doctors take the time to review your health history, run appropriate labs, and design a peptide-based weight management plan that fits your body. Whether Sema or Tirz is the right starting point depends on your individual picture – not a template.
Ready to Discuss Your Options?
If you have been trying to decide between Sema and Tirz for weight management, or have questions about how Reta may factor in when available, our East Valley team is here to help. Serving Mesa, Gilbert, Chandler, Tempe and the greater Phoenix area, we build personalized plans based on your labs, history and goals – not just the latest medication headlines.
Call now to schedule your consultation.
No. The SURMOUNT-5 trial did show greater average weight reduction with Tirz (20.2 percent) compared to Sema (13.7 percent) over 72 weeks, but individual response varies significantly. Some patients respond very well to Sema and never need to consider a stronger option. The best medication is the one that fits your body, tolerance and long-term plan – not the strongest one on average.
Reta is currently in clinical development. Phase 3 trials have shown promising weight reduction results – up to 22.5 percent in obesity trials – but as of 2026, Reta has not yet received FDA approval for weight management. Timing for availability depends on ongoing regulatory review.
In many cases, yes – but this decision should be made with your prescribing provider based on your response, side effects and overall clinical picture. Switching medications is not something to do independently. A proper transition protocol matters for both safety and progress.
Gastrointestinal symptoms – nausea, digestive discomfort, occasional constipation or diarrhea – are the most common side effects of all three medications, especially during the first weeks or during dose increases. Proper dose titration significantly reduces both severity and duration.
All three medications can help regulate appetite and metabolic response even without major lifestyle changes. However, long-term results are consistently better when the medication is paired with adequate protein intake, sleep, stress management and regular movement. The medication supports the body’s signals – the lifestyle sustains the results.
Compounded versions prepared by licensed pharmacies under proper medical supervision can be an option in certain situations. However, they should never be sourced from unverified online providers. Compounding pharmacies vary significantly in quality control, and patient safety depends heavily on the supervising provider and the pharmacy’s practices.